Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72. RESULTS: A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). The least-squares mean change in waist circumference was -18.4 cm (95% CI, -19.6 to -17.2) with tirzepatide and -13.0 cm (95% CI, -14.3 to -11.7) with semaglutide (P<0.001). Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%. The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation. CONCLUSIONS: Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tirzepatide also leads to greater weight loss than semaglutide for people with type 2 diabetes 14 and than liraglutide for people with obesity.15”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“In the STEP-8 trial, 70 semaglutide 2•4 mg/week led to greater weight loss (a 15•8% reduction) compared with liraglutide 3•0 mg once daily (a 6•4% reduction); in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7%”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7% )”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“Similar differences in effectiveness are found when looking at reductions in waist circumference, systolic blood pressure, and serum triglycerides, with differences in effect sizes reflecting the differences in weight loss in response to liraglutide, semaglutide, and tirzepatide treatment.15,70”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“The efficacy of GLP-1 receptor agonists (GLP-1 RAs) in older adults has been robustly demonstrated in randomized controlled trials (RCTs) [34], providing strong evidence for their use in managing obesity and related comorbidities in individuals aged over 65.”
From A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass (2026) · cites this paper as [34]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Whelton, P. K. (2002) · JAMA · doi:10.1001/jama.288.15.1882 · Cited by 1,473
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Self-citationTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Cited by
Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505928 · Cited by 223
Celletti, F., Farrar, J., & De Regil, L. (2026) · JAMA · doi:10.1001/jama.2025.24288 · Cited by 153
Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00226-8 · Cited by 119
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Dahl, K., Toubro, S., Dey, S., Duque do Vale, R., Flint, A., Gasiorek, A., Heydorn, A., Jastreboff, A. M., Key, C., Petersen, S. B., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01185-7 · Cited by 80
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
“Gastrointestinal adverse events such as nausea, diarrhea, constipation and vomiting are seen with all GLP-1 medicines and, to date, rates are similar with semaglutide versus tirzepatide 10,11,17 .”
Krüger, N., Schneeweiss, S., Desai, R. J., Sreedhara, S. K., Kehoe, A. R., Fuse, K., Hahn, G., Schunkert, H., & Wang, S. V. (2026) · Nature Medicine · doi:10.1038/s41591-025-04102-x · Cited by 48
“Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist with rapidly growing use, has demonstrated even greater effects on glycemic control and weight loss 13–15 .”
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 153
New Molecules and Indications for GLP-1 Medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · JAMA · doi:10.1001/jama.2025.14392 · Cited by 50
Billings, L. K., Hsia, S. H., Bays, H. E., Tidemann‐Miller, B., O’Hagan, J., Tham, L. S., Butler, A., KAZDA, C. M., Mather, K. J., & Coşkun, T. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02155-5 · Cited by 47
Gunnarsson, S., Vito, O., & Unwin, R. J. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00499.2025 · Cited by 51
Merola, J. F., Mease, P. J., Kivitz, A., Sattar, N. A., Coates, L. C., Aletaha, D., Kartman, C. E., Fischer, P., Sun, L., Martínez-Osuna, P., et al. (2026) · Arthritis & Rheumatology · doi:10.1002/art.70134 · Cited by 51
Moiz, A., Zolotarova, T., Filion, K. B., & Eisenberg, M. J. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpaf205 · Cited by 26
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 44
“Tirzepatide also achieved significantly greater reductions in waist circumference and higher proportions of participants achieving ≥ 10%, ≥ 15%, ≥ 20%, and ≥ 25% weight loss [36].”
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
“Discon-tinuation for adverse events was 6.1% for tirzepatide versus 8.0% for semaglutide [76].”
InfluentialMamas, M. A., Bays, H., Li, R., Upadhyay, N., Irani, T., Senyucel, C., Dunn, J. P., & Liu-Seifert, H. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf117 · Cited by 24
“11 After 72 weeks of treatment, participants in the tirzepatide-treated arm had a least-squares mean (LS mean) weight reduction of 20.2% vs. 13.7% in the semaglutide-treated arm ( P 0.001), 11 adjusted for baseline weight, prediabetes status, BMI group ( 35, ≥ 35 kg/m 2 ), and sex.”
InfluentialSelf-citationSievenpiper, J. L., Ard, J. D., Blüher, M., Chen, W., Dixon, J. B., Fitch, A., Gigliotti, L., Khunti, K., Lecube, A., Lean, M., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100228 · Cited by 56
“In clinical trials, semaglutide and tirzepatide have demonstrated mean weight reductions of 15 – 25 % at 12 – 36 months, close to that achieved with some forms of bariatric surgery [16 – 19].”
Aronne, L. J., Horn, D. B., le Roux, C. W., Chao, A. M., Ho, W., Halpern, B., Griffin, R., Xie, C., Valderas, E. G., Lee, C. J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04386-7 · Cited by 22
Self-citationKanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 47
GLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 35
“First, multiple-agonist therapies, including the FDA-approved GLP-1/GIP receptor coagonist tirzepatide, are more effective at promoting weight loss than GLP-1R monoagonists, including semaglutide (135–137).”
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
“In patients with obesity without diabetes, tirzepatide led to greater weight loss than semaglutide 366,384 , improved exercise capacity and quality of life in patients with HFpEF compared with placebo 385 , and lowered the risk of a composite of death from cardiovascular causes or worsening HF in…”
Horn, D. B., Aronne, L. J., Wharton, S., Bays, H. E., le Roux, C. W., Srinath, R., Valderas, E. G., Arad, A. D., Das, S., Dunn, J. P., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00656-2 · Cited by 50
Self-citationMetabolic Messenger: growth differentiation factor 15
Breit, S. N., & Tsai, V. W.-W. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01353-3 · Cited by 26
“Despite recent advances in obesity treatment using GLP1 agonist therapy 144,145 , these therapies often cause side effects such as gastrointestinal adverse reactions and weight regain upon cessation of therapy, underscoring the need for more sustained weight management interventions.”
Souto, M., Gonçalves, T. C., & Cotter, J. B. (2025) · Nutrients · doi:10.3390/nu17142310 · Cited by 26
“In clinical trials, such as SURMOUNT-1 and SURPASS, it demonstrated superior weight loss compared to other existing therapies [129–132].”
Ciudin, A., Johansson, E., Zimner‐Rapuch, S., Dimitriadis, G. K., Bertrand, M., Curteis, T., Clark, L. J., Fan, L., Sapin, H., & Bergmann, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16508 · Cited by 27
“28 A recent cohort study found that tirzepatide was significantly more effective than semaglutide for weight management in participants with T2D; however, the study pooled results across treatment doses.”
Spreckley, M., Ruggiero, C. F., & Brown, A. (2026) · Obesity Reviews · doi:10.1111/obr.70079 · Cited by 16
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
Sheth, K., Kim, S., Porterfield, L. R., Virani, S. S., Wadhwani, S., & Vaughan, E. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01319-6 · Cited by 21
“Tirzepatide 10 mg and 15 mg weekly resulted in a mean weight reduction of 20.2% compared to 13.7% with semaglutide 17 mg or 2.5 mg weekly ( p < 0.001) [40].”
InfluentialSabatella, L., Ortega, P., Valentí, V., Rotellar, F., Pagola, A. U., Ahmed, A., Purkayastha, S., Tuero, C., Blanco, N., & Landecho, M. F. (2025) · Obesity · doi:10.1002/oby.70100 · Cited by 32
“In the SURMOUNT-5 trial, tirzepatide demonstrated superior efficacy to semaglutide at 72 weeks in adults with obesity without diabetes [6].”
Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures
Liu, Y., Walzer, D., Schmitz, S. H., Shukla, A. P., Ma, X., Chirko, D., Pipia, I., Sathi, S., Shukairy, U., Greenberg, M. D., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag052 · Cited by 34
Nissen, S. E., Wolski, K., D’Alessio, D. A., Weerakkody, G. J., Kiljanski, J. I., Wiese, R. J., Pavo, I. J., Cariou, B., & Nicholls, S. J. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0767 · Cited by 25
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
Seier, S., Stamp‐Larsen, K., Jensen, S. B. K., Torekov, S. S., & Gudbergsen, H. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70096 · Cited by 15
“Time was modelled using splines with inner knots placed at weeks 12, 26, 39, and 52 and outer knots weeks 1 and 64.”
Scragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects
Cardoso, P., Dennis, J., & Pearson, E. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194742 · Cited by 20
“Another meta-analysis suggested that while GLP-1RA cardio-There is also increasing evidence of clinically meaningful differences in GLP-1RA outcomes by sex, with women showing both more weight loss (9, 11, 35) and a greater glycemic response (36, 37) than men.”
Lebwohl, M., Blauvelt, A., Kartman, C. E., Leatherwood, C., Gordon, K. B., Sattar, N. A., Puig, L., Merola, J. F., Siu, K., Wang, R., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.1753 · Cited by 31
Fitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100205 · Cited by 14
Monzo, L., Savarese, G., Müllens, W., Abdin, A., Bozkurt, B., Chioncel, O. D., Hadidi, S. E., Gorter, T. M., Inciardi, R. M., Petrie, M. C., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70082 · Cited by 17
“In a recent comparative weight-loss study comparing the two agents, overall discontinuation rates were similar, although gastrointestinal symptoms prompted withdrawal more frequently with semaglu-tide than with tirzepatide (6.6% vs. 2.7%).”
InfluentialBarana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“%) and waist circumference reduction [23].”
Ciudin, A., Baker, J. L., Belančić, A., Busetto, L., Diker, D., Fábryová, Ľ., Frühbeck, G., Goossens, G. H., Gordon, J., Monami, M., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04397-4 · Cited by 26
GLP-1 Receptor Agonists in Heart Failure
Rahmani, A. R., Dhaliwal, S., Pastena, P., Kazakov, E., Jayaseelan, K., & Kalogeropoulos, A. P. (2025) · Biomolecules · doi:10.3390/biom15101403 · Cited by 19
“%) and received approval for obesity treatment in 2023 [138,139].”
Park, S. K., & Choi, J. H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217586 · Cited by 13
“In certain clinical trials, tirzepatide produced greater weight loss than semaglutide, with mean reductions of 20.2% compared to 13.7%, respectively [138].”
InfluentialAl‐Ozairi, E., Irshad, M., Alkandari, J., SOJAN, L. G., Alroudhan, D., Alotaibi, N., & le Roux, C. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70172 · Cited by 14
“11,13 The dose-dependent weight reductions are consistent with earlier trials, including the SURPASS program and STEP trials.”
Self-citationObesity and Atrial Fibrillation: From Mechanisms to Treatment
Dziano, J. K., Ariyaratnam, J., Middeldorp, M. E., Sanders, P., & Elliott, A. D. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.08.003 · Cited by 17
Shukla, A. P., Dunn, J. P., Valderas, E. G., Fraseur, J. G., Karanikas, C. A., & Hunter, T. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70215 · Cited by 18
“38 Briefly, SURMOUNT-5 was a phase 3b multicenter, randomized, parallel-arm, open-label, controlled, 72-week trial that included adults aged 18 years or older, with a BMI ≥ 30 kg/m 2 or BMI ≥ 27 kg/m 2 with at least one weight-related complication (hypertension, dyslipidaemia, obstructive sleep…”
InfluentialSelf-citationBabazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
“…the efficacy and safety of tirzepatide noting significant body weight (BW) loss percentages between 12.8% and 18.4% [23 – 28] compared with placebo and bolstering even greater weight loss with tirzepatide than semaglutide in a head-to-head comparison, 20.2% compared with 13.7%, respectively [29].”
InfluentialHydrophobic Tag-Assisted Liquid-Phase Synthesis of Tirzepatide
Pang, Z.-J., Mao, C.-Y., Feng, T., & Dong, L. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c03314 · Cited by 12
Moscucci, F., Baratta, F., Pastori, D., Menichelli, D., Mattioli, A. V., Gallina, S., Lospinuso, I., Sciomer, S., Piccirillo, G., & Desideri, G. (2026) · Nutrients · doi:10.3390/nu18040632 · Cited by 11
“The efficacy of GLP-1 receptor agonists (GLP-1 RAs) in older adults has been robustly demonstrated in randomized controlled trials (RCTs) [34], providing strong evidence for their use in managing obesity and related comorbidities in individuals aged over 65.”
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
“…agonist (dual GIP/ GLP-1RA) are associated with gastrointestinal adverse effects including nausea, diarrhea, constipation, and dyspepsia, 60–62 which may be managed by decreasing portion sizes, decreasing intake of high-fat foods, increasing intake of high-fiber foods, avoiding long…”
Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C. J., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J., Selzer, F., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03609 · Cited by 20
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Farrugia, M. A., Pini, E., Tran, A., Chevalier, N., Anty, R., & Gual, P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00646-8 · Cited by 12
“Tirzepatide showed a superior body weight reduction compared with semaglutide [102].”
Lifestyle Modification and Incretin-Based Therapy for Obesity
Kushner, R. F., Chao, A. M., & Wadden, T. A. (2026) · JAMA · doi:10.1001/jama.2026.4106 · Cited by 11
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“…receptor (GIPR)– GLP1R co-agonist, has shown greater weight-lowering efficacy in people with obesity than semaglutide, reaching mean placebo-corrected weight loss in the region of 15–20% 14,18 , and additional benefits on certain obesity-related complications 19,20 and diabetes prevention 21 .”
Hsu, Y.-H., Liang, Y.-C., Chan, K.-C., Chou, Y.-H., Wu, H., & Ou, H. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112995 · Cited by 21
Lessons from incretin-based therapy in MASH and obesity
Tilg, H., & Targher, G. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01096-2 · Cited by 10
“Finally, the study by Aronne et al. suggests that in the future, even more potent incretin agonists might be available for the treatment of MASH, including dual and even triple incretin polyagonists 4 .”
Insights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
Self-citationGLP-1 Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management
Xande, J. G., & del Giglio, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167744 · Cited by 14
“Although direct head-to-head comparisons are absent, these findings indicate that weight loss in BC patients is less significant compared to non-cancer populations [41].”
InfluentialExploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
Hammad, B. F., Zafar, N., Ullah, M., Faisal, S. J., Iftikhar, F., Waheed, H., Muzaffar, M. W., Ahmed, K., Ashraf, F., Zahid, K., et al. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1590530 · Cited by 14
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management
Acierno, C., Nevola, R., Barletta, F., Zielińska, K., Rinaldi, L., Sasso, F. C., Conte, C., Adinolfi, L. E., & Caturano, A. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001365 · Cited by 14
Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes
Derington, C. G., Sarwal, A., Wei, G., Hartsell, S. E., Throolin, M. J., Singh, R., Nevers, M. R., Zhang, C., Katkam, N., Takyi, A., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.37297 · Cited by 13
Optimizing GLP-1 therapies for obesity and diabetes management
Noronha, J. C., Gaal, L. F. V., Neeland, I. J., Fitch, A., Pfeiffer, A. F. H., Chiavaroli, L., Kendall, C. W. C., & Sievenpiper, J. L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100222 · Cited by 20
“GI symptoms are the most common adverse effects of GLP-1 therapies, with nausea, constipation, diarrhea, and vomiting occurring in around 40 % of patients [11,30 – 32].”
Thermogenesis in Adipose Tissue: Adrenergic and Non-Adrenergic Pathways
Hossain, M. A., Poojari, A., & Rabiee, A. (2026) · Cells · doi:10.3390/cells15020131 · Cited by 10
“Survotide and Mazdutide are both weekly GLP-1 and glucagon agonists that have shown promising results for weight loss in obese and diabetic participants, respectively [252].”
The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
Kounatidis, D. C., Vallianou, N. G., Rebelos, E., Vallianou, K., Diakoumopoulou, E., Makrilakis, K., & Tentolouris, N. (2025) · Biomolecules · doi:10.3390/biom15091284 · Cited by 15
“More recently, tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, has demonstrated superior weight-reducing effects compared with both placebo and semaglutide, particularly in the SURMOUNT trials, with these benefits sustained for up to 72 weeks [79–81].”
Herman, R., Jensterle, M., Horvat, S., Ležaić, L., Snoj, Ž., Pušnik, I., Goričar, K., Cör, A., Pušnik, L., Mlačnik, V., et al. (2025) · Trials · doi:10.1186/s13063-025-09045-9 · Cited by 14
“Less frequent but serious risks may include pancreatitis, gallbladder-related events, and hypoglycemia, particularly in patients with concurrent antidiabetic therapies [37, 48–50].”
Wadden, T., Oquendo, M. A., Kushner, R. F., Cao, D., Karanikas, C. A., Kechter, A., & Murphy, M. A. (2026) · Obesity · doi:10.1002/oby.70122 · Cited by 16
“This is the first report to focus on the psychiatric events associated with the use of a combined GIP/GLP-1RA, whose dual mechanism of action likely contributes to its larger weight loss as compared with GLP-1 receptor agonism alone [31].”
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults
Hsu, A. H.-C., Ramirez, P. T., Chang, Y.-H., Chiang, Y. C., Santía, M. C., Meschini, T., Mateo-Kubach, P., Suri, A., & Kamat, A. A. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.04.013 · Cited by 12
Ahmed, W., Gandhi, O. H., Yu, N. S., Brant, J. A., Hwa, T. P., Bagley, L. J., Tamhankar, M. A., Feroze, A. H., & Choudhri, O. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.125711 · Cited by 8
Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis
Basile, C., Merolla, A., Mancusi, C., Luca, C. D., Fucile, I., Canonico, M. E., Giugliano, G., Orso, F., Morisco, C., & Esposito, G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf560 · Cited by 17
Epidemiology of cardiovascular–kidney–metabolic syndrome
Mavromatis, L. A., & Grams, M. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01078-w · Cited by 14
Schiavo, L., Santella, B., Mingo, M., Rossetti, G., Orio, M., & Pilone, V. (2025) · Nutrients · doi:10.3390/nu17152409 · Cited by 14
“All participants had previously failed at least one structured dietary intervention aimed at weight reduction [6,21–24].”
Semaglutide and Tirzepatide to Treat Obesity
Greenway, F. L. (2025) · New England Journal of Medicine · doi:10.1056/nejme2507452 · Cited by 7
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
Troshina, E. A., Antsiferov, M. B., As, A., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2025) · Problems of Endocrinology · doi:10.14341/probl13677 · Cited by 14
“Важно отметить, что частота серьезных нежелательных явлений, приведших к прекращению терапии (включая панкреатит и сердеч-но-сосудистые события), была очень низкой и не разли-чалась между группами [33].”
LEAP2 as a therapeutic target in obesity and cardiometabolic disorders
Holm, S. K., Johansen, V. B. I., & Clemmensen, C. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-10007-4 · Cited by 11
“As evidence for hepatic GHSR1a expression remains scarce [63, 123, 153, 154 ], the effects of LA-LEAP2 on enhancing efficacy through complementary mechanisms [15, 148–152].”
Yılmaz, N., & Baştemir, M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s584175 · Cited by 15
“1”
Revolution in Stroke Treatment Over 50 Years and Predicting Stroke Care in 2050
Broderick, J. P. (2025) · Stroke · doi:10.1161/strokeaha.125.052583 · Cited by 7
Shaping the future of cardiometabolic innovation: advances and opportunities
Clemmensen, C., Gerhart‐Hines, Z., Schwartz, T. W., Zierath, J. R., & Sakamoto, K. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01343-5 · Cited by 7
Johnson, H. H., Clift, A. K., Reisel, D., & Huang, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70244 · Cited by 7
“While clinical studies such as the SURMOUNT and STEP trials have established the safety profiles of these medications, 6,16,17 real-world safety data, particularly in the context of digital health integration, remain limited.”
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
“Within the SURMOUNT trials programme 93 , the SURMOUNT-4 trial tested the effect of tirzepatide withdrawal on body weight, also reporting data on HbA 1c as an exploratory end point; 783 participants were enrolled in an open-label, lead-in period and received once-weekly tirzepatide for 36 weeks.”
Patil, S., Jha, N., & Jha, M. K. (2026) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2026.100671 · Cited by 24
Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf779 · Cited by 6
“10 However, it remains unclear whether these larger reductions in glycaemia and body weight also translate into a larger reduction in cardiovascular risk.”
Fiorucci, S., & Urbani, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2546812 · Cited by 10
“…trialed against sema-glutide: 751 adult obese patients without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks [53].”
InfluentialRichards, R., Lunt, W., Whitman, M., Spaltro, G., & Hall, R. (2025) · JMIR Formative Research · doi:10.2196/81912 · Cited by 15
“Previous studies comparing between the 2 drugs have shown mixed results, with some real-world studies reporting lower weight change outcomes [31,32].”
Tirzepatide for adults living with obesity
Franco, J. V. A., Guo, Y., Varela, L. B., Aqra, Z., Alhalahla, M., Rodriguez, M. M., Salvador-Oscco, E., Araujo, B. P., Banda, S., Liquitay, C. M. E., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016018 · Cited by 23
DePietro, R., Bertarelli, I., Zink, C. M., Canfield, S. M., Smith, J., & McElroy, J. A. (2026) · Healthcare · doi:10.3390/healthcare14020186 · Cited by 13
“…conducted in 2025, five years after semaglu-tide (NovoNordisk A/S, Plainsboro, NJ, USA) and two years after tirzepatide (Eli Lilly and Company, Indianapolis, IN USA) received FDA approval for the treatment of obesity, the data reflect a moment at which longitudinal safety data remained limited [4].”
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 27
Self-citationBeyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide
Rzepiński, Ł., Tywoniuk, A., Jaraczewska, J., Al-Shaer, A., & Wiciński, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412028 · Cited by 8
“Therefore, the drug improves glycemic control and weight loss compared with the GLP-1 receptor agonist—semaglutide [4,5].”
Alsalloum, M. A., Albekery, M. A., & Alhomoud, I. S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1630160 · Cited by 12
Bujdei-Tebeică, I., Mihai, D. A., Stoian, A. P., Ștefan, S., Stoicescu, C. I., & Serafinceanu, C. (2025) · Medicina · doi:10.3390/medicina61081399 · Cited by 11
“Interpretative comparisons are now possible through the results of SURMOUNT-5, where tirzepatide emerged as superior to semaglutide 2.4 mg regarding weight loss efficacy in adult patients with obesity [67].”
InfluentialYokote, K., Fukushima, Y., Shingaki, T., Oura, T., & Ogawa, W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70315 · Cited by 6
Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide
Bernardi, J. C., Cavalcante, D. V. S., Huntermann, R., Molinari, M. E., Zanon, L. Z., Khater, J., Gomez, V. A., & Fischer‐Bacca, C. O. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70192 · Cited by 5
Alqatari, S. G., Alwaheed, A., Hasan, M. A., Argan, R. A., Alabdullah, M. M., & Shubbar, M. D. A. (2025) · Medicina · doi:10.3390/medicina61071292 · Cited by 11
“GLP-1 receptor agonists such as semaglutide and dual agonists like tirzepatide have shown average weight reductions of up to 20% in clinical trials [15]— results that approach those seen with surgical interventions.”
Beyond a singular focus on GLP-1: why we need a new nomenclature now
Muskiet, M. H. A., & Smits, M. M. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00197-4 · Cited by 6
A treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT ‐5 trial
le Roux, C. W., Busetto, L., Aronne, L. J., Horn, D. B., Dimitriadis, G. K., Falcón, B. L., García‐Pérez, L., Valderas, E. G., Gibble, T. H., Şenyücel, Ç., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70531 · Cited by 5
Self-citationPharmacological Management of Diabesity: Current and Emerging Therapies
Galasso, M., Caporusso, M., Volatile, A., Verde, L., Esposito, K., Giorgino, F., Perrini, S., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-025-00681-5 · Cited by 6
The evolving role of metabolic and bariatric surgery in contemporary clinical practice
Panichella, G., Gentile, F., Nannipieri, M., & Emdin, M. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf787 · Cited by 6
Cerchi, E., Santo, P. A. D. E., de Oliveira, M. C., Janovsky, C. C. P. S., & Halpern, B. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01920-4 · Cited by 9
Colognesi, M., Gabbia, D., Signor, A., Sarill, M., Centofanti, L., Rinaldi, A., Cascione, L., Nunziata, S., Banzato, M., Mattarei, A., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108080 · Cited by 8
Drexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 7
Banerjee, M., Pal, R., & Pal, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70187 · Cited by 9
Metadata
- Authors
- Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P.
- Affiliations
- Weill Cornell Medicine (US)
- University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston
- Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin
- University of California, Los Angeles (US)
- Eli Lilly, Indianapolis
- Eli Lilly (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-07-03
- Volume
- 393
- Issue
- 1
- Pages
- 26-36
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4410277932
- Cited by
- 634
- References
- 40
- Citations by year
- 2026: 448 · 2025: 186
- FWCI
- 355.83
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- eCommons (Cornell University) (submittedVersion, cc-by-nc-nd)
- Funders
- Eli Lilly and Company (NA)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- tirzepatide, semaglutide, obesity, weight loss, waist circumference, GLP-1 receptor agonists, GIP/GLP-1 receptor agonist, gastrointestinal adverse effects, non-diabetic obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Adult, Aged, Body Weight, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents, Maximum Tolerated Dose, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.